Showing 3581-3590 of 4062 results for "".
- New Educational Resource On Importance of Eye Protection in Sports/Recreational Activititeshttps://modernod.com/news/new-educational-resource-on-importance-of-eye-protection-in-sports-recreational-activitites/2479046/The International Sports Vision Association (ISVA) and Zyloware Eyewear announced the launch of Protect. Prevent. Play., a new educational resource designed to help eye care professionals educate parents, coaches, teachers, athletic trainers and athletes of all ages and skill levels abou
- Oasis Medical Launches Cyber Platform MY OASIS to Support Dry Eye Clinicshttps://modernod.com/news/oasis-medical-launches-cyber-platform-my-oasis-to-support-dry-eye-clinics/2479021/Oasis Medical is formally launching its new patented cyber platform MY OASIS at SECO International 2021, booth #722. MY OASIS is a cyber platform for eye care providers to build their brand as a dry eye resourc
- NeurOptics Launches Pupillometry Program at Vanderbilt University Medical Centerhttps://modernod.com/news/neuroptics-launches-pupillometry-program-at-vanderbilt-university-medical-center/2479015/NeurOptics recently announced that its NPi-200 pupillometers and the Neurological Pupil Index (NPi) are now being used in the Neurological Intensive Care Unit at Vanderbilt University Medical Center, in Nashville, Tennessee, as an important measurement for managing patients with brain injury.
- Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen for Dry AMD With Geographic Atrophyhttps://modernod.com/news/lineage-cell-therapeutics-presents-additional-interim-data-on-opregen-for-dry-amd-with-geographic-atrophy/2479007/Lineage Cell Therapeutics announced new positive interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal
- Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestonehttps://modernod.com/news/nicoxs-ncx-470-mont-blanc-phase-3-glaucoma-trial-reaches-50-enrollment-milestone/2478999/Nicox announced that 50% of patients in the Mont Blanc NCX 470 phase 3 glaucoma clinical trial have now been randomized out of a target of 670, with topline results currently on track to be announced during Q2 2022. “We have been successful in maintaining a good recruitment rate in the Mon
- Santen EMEA Appoints Dr. Ioana Grobeiu as Vice President, Medical Affairshttps://modernod.com/news/santen-emea-appoints-dr-ioana-grobeiu-as-vice-president-medical-affairs/2479000/Santen EMEA has announced the appointment of Dr. Ioana Grobeiu as Vice President, Medical Affairs. With over 20 years of experience in pharmaceuticals, Dr. Grobeiu will lead the medical affairs strategy and report to Luis Iglesias, President and Head of Santen EMEA. Dr. Grobeiu will delive
- SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Rochehttps://modernod.com/news/semathera-enters-into-a-research-collaboration-and-exclusive-license-agreement-with-roche/2478997/SemaThera announced the signing of a multi-year research collaboration and licensing agreement with Roche to advance SemaThera’s new class of biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases. Terms of the deal were not disclosed. “We are very
- NovaSight Announces First Pivotal Study for Lazy-Eye Digital Treatment Against Gold Standard Patchinghttps://modernod.com/news/novasight-announces-first-pivotal-study-for-lazy-eye-digital-treatment-against-gold-standard-patching/2478980/Israeli startup NovaSight has announced that it is running a large, pivotal multicenter randomized controlled trial to assess the safety and effectiveness of an eye-tracking-based treatment for amblyopia (lazy eye). This is the first pivotal study of its kind in children against the gold standard
- Kala Pharmaceuticals Announces Preferred Position for Eysuvis on Cignahttps://modernod.com/news/kala-pharmaceuticals-announces-preferred-position-for-eysuvis-on-cigna/2478977/Kala Pharmaceuticals announced that Cigna has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a preferred brand on its commercial formulary, effective May 15, 2021. “We are pleased to announce the addition of Eysuvis to Cigna’s preferred formulary, reflecting a signifi
- J&J’s Coronavirus Vaccine Garners WHO Emergency-Use Listinghttps://modernod.com/news/jjs-coronavirus-vaccine-garners-who-emergency-use-listing/2478968/Johnson & Johnson said that the World Health Organization (WHO) has issued an emergency-use listing for its single-dose coronavirus vaccine Ad26.COV2.S to prevent COVID-19 in people 18 years and older. Chief scientific officer Paul Stoffels stated that “achieving this important prerequi